REG - Hutchmed China Ltd - Result of AGM

HUTCHMED (China)Announcement

10/05/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240510:nRSJ0210Oa&default-theme=true

RNS Number : 0210O  Hutchmed (China) Limited  10 May 2024

Annual General Meeting held on May 10, 2024 - Poll Results

 

 

Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 10, 2024: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and
the special resolution put to its Annual General Meeting ("AGM") held on May
10, 2024 were duly passed.  The poll results of the resolutions were as
follows:

 

 

                                                                                              Number of Votes (%)*

                                                                                                                                  Passed by Shareholders

 Ordinary Resolutions

              For                                                                             Against      Withheld(#)

 1.           To consider and adopt the audited financial statements, and the reports of the  554,454,067  38,180,450    218,278  Yes
              directors and independent auditors for the year ended December 31, 2023.

                                                                               (93.5575%)   (6.4425%)

 2(A).        To re-elect Mr TO Chi Keung, Simon as a director.                               562,917,369  29,905,093    30,333   Yes

                                                                                              (94.9555%)   (5.0445%)

 2(B).        To re-elect Dr Weiguo SU as a director.                                         592,306,222  516,240       30,333   Yes

                                                                                              (99.9129%)   (0.0871%)

 2(C).        To re-elect Mr CHENG Chig Fung, Johnny as a director.                           592,007,486  814,976       30,333   Yes

                                                                                              (99.8625%)   (0.1375%)

 2(D).        To re-elect Dr Dan ELDAR as a director.                                         591,101,915  1,720,547     30,333   Yes

                                                                                              (99.7098%)   (0.2902%)

 2(E).        To re-elect Ms Edith SHIH as a director.                                        588,968,013  3,854,454     30,328   Yes

                                                                                              (99.3498%)   (0.6502%)

 2(F).        To re-elect Ms Ling YANG as a director.                                         584,012,135  8,810,327     30,333   Yes

                                                                                              (98.5138%)   (1.4862%)

 2(G).        To re-elect Mr Paul Rutherford CARTER as a director.                            534,646,546  58,175,756    30,493   Yes

                                                                                              (90.1866%)   (9.8134%)

 2(H).        To re-elect Mr Graeme Allan JACK as a director.                                 570,023,306  22,799,126    30,363   Yes

                                                                                              (96.1541%)   (3.8459%)

 2(I).        To re-elect Professor MOK Shu Kam, Tony as a director.                          582,250,508  10,571,949    30,338   Yes

                                                                                              (98.2167%)   (1.7833%)

 3.           To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP  592,416,337  391,725       44,733   Yes
              as the Auditors of the Company for Hong Kong financial reporting and U.S.

              financial reporting purposes, respectively, and to authorize the Directors to   (99.9339%)   (0.0661%)
              fix the Auditors' remuneration.

 Special Resolution
 4.           To grant a general mandate to the Directors to issue additional shares of the   589,480,694  3,329,371     42,730   Yes

            Company.^

                                                                               (99.4384%)   (0.5616%)

 Ordinary Resolution
 5.           To grant a general mandate to the Directors to repurchase shares of the         592,794,880  15,185        42,730   Yes
              Company.^

                                                                               (99.9974%)   (0.0026%)

 

*  Percentages rounded to 4 decimal places.

(#) A vote withheld is not a vote in law and is not counted in the calculation
of the proportion of the votes for and against a resolution.

^ The full text of Resolutions 4 and 5 are set out in the Notice of AGM.

 

Notes:

 

(1)       All directors of the Company, namely Mr TO Chi Keung, Simon,
Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Dr Dan ELDAR, Ms Edith SHIH, Ms Ling
YANG, Mr Paul Rutherford CARTER, Mr Graeme Allan JACK and Professor MOK Shu
Kam, Tony, attended the AGM, either in person or by means of electronic
facilities.

 

(2)       Number of shares entitling the holders to attend and vote on
all the resolutions at the AGM: 871,264,820 shares.

 

(3)       Number of shares entitling the holders to attend and abstain from
voting in favour as set out in Rule 13.40 of the Rules Governing the Listing
of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")
at the AGM: Nil.

 

(4)       Number of shares for holders required under the Listing Rules
to abstain from voting at the AGM: Nil.

 

(5)       The scrutineer for the poll at the AGM was Computershare
Investor Services (Jersey) Limited, the Principal Share Registrar of the
Company.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. Іt is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Іt has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three medicines marketed in China, the first of which is
also marketed in the U.S. For more information, please visit:
www.hutch‑med.com (https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS

 

 Investor Enquiries                                                    +852 2121 8200 /
                                                                       ir@hutch-med.com (mailto:ir@hutch-med.com)
 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting                                +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                                       +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                       (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                                    +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                       (mailto:HUTCHMED@brunswickgroup.com)
 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon       +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGURSARSOUVAAR